The effect of olive oil on oxidative damage in European populations

Conditions

Oxidative damage to lipids Nutritional, Metabolic, Endocrine

Hernáez Á, Remaley AT, Farràs M, Fernández-Castillejo S, Subirana I, Schröder H, Fernández-Mampel M, Muñoz-Aguayo D, Sampson M, Solà R, Farré M, de la Torre R, López-Sabater MC, Nyyssönen K, Zunft HJ, Covas MI, Fitó M.

2015-07-0161 citations

10.3945/jn.115.211557

Protection of LDL from oxidation by olive oil polyphenols is associated with a downregulation of CD40-ligand expression and its downstream products in vivo in humans.

Castañer O, Covas MI, Khymenets O, Nyyssonen K, Konstantinidou V, Zunft HF, de la Torre R, Muñoz-Aguayo D, Vila J, Fitó M.

2012-03-2176 citations

10.3945/ajcn.111.029207

The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial.

Covas MI, Nyyssönen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, Gaddi A, de la Torre R, Mursu J, Bäumler H, Nascetti S, Salonen JT, Fitó M, Virtanen J, Marrugat J, EUROLIVE Study Group.

2006-09-01452 citations

10.7326/0003-4819-145-5-200609050-00006

Interventions

Three types of olive oil with differences in their phenolic content (25 ml per day). Intervention periods of three weeks separated by two week-washout periods.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy, non-smoking, voluntary men aged 20 - 60 years

Exclusion criteria

Exclusion criteria: 1. Intake of antioxidant supplements 2. Intake of acetosalicylic acid 3. Intake of any other drug with established antioxidative properties 4. Athletes with high physical activity (greater than 3000 kcal per week in leisure-time physical activity) 5. Obesity (Body Mass Index [BMI] greater than 32 kg per m^2) 6. Hypercholestrolemia greater than 8.0 mmol per litre or dyslipemia therapy indication 7. Diabetes 8. Multiple allergies 9. Celiac or other intestinal diseases 10. Any condition that limits the mobility of the subject making study visits impossible 11. Life threatening illnesses such as cancer or a severe disease with a less than 3-year expectancy 12. Other diseases or conditions that could worsen adherence to the measurements or treatments 13. Vegetarians and people following special diets

Design outcomes

Primary

Measure	Time frame
Oxidative damage to lipids and Deoxyribonucleic Acid (DNA)	—

Secondary

Measure	Time frame
Lipids and lipoprotein metabolism	—

Countries

Spain

Outcome results

None listed